Aug 13, 2026 earnings call — Proteus launch delayed; added design cycle
Company moved Proteus launch to the second quarter of 2027 and announced a targeted reduction in force of approximately 20%.
Revenue $0.0B (est $0.0B) · EPS $-0.11 (est $-0.11)
Key quotes
"We have updated the Proteus launch timeline from the end of 2026 to the second quarter of 2027."
"These learnings have led us to an important strategic shift, evolving from a single generic kit to a suite of application-oriented kits that can be used individually or in combination to optimize sequencing performance for specific customer use cases."
"As part of this disciplined approach, earlier today we announced operating expense actions, including a targeted reduction in force representing approximately 20% of the total company headcount."
Analyst Q&A 5
reason for product change and timing
Q (Scott Henry · Alliance Global Partners): He asked what caused the design change and whether the company is comfortable with the Q2 '27 target. He also asked who will be the early users and whether R&D spend will change.
A: Management said the change came from their internal assessment to improve repeatability, performance and manufacturability, not from new customer feedback. They completed a thorough review and believe the timeline of Q2 reflects the work required, though complex programs are never 100% certain. They expect early adopters to be a mix of academic researchers, biopharma, government/military and some industrial users, and R&D spending should stay fairly consistent with prior quarters with some adjustments.
"It wasn't driven by some sort of new feedback from customers that caused us to believe we need to add some capabilities we weren't planning for." — Jeffrey Hawkins (CEO)
why extra design cycle and effects
Q (Michael King · Rodman & Renshaw): He asked whether the extra design cycle came from prototype demo runs or scale-up for customer delivery and how it affects the early access program. He also asked if reagents are affected, whether Platinum Pro units can be used now, and the timing for the full set of amino acids.
A: Management said the extra cycle came from testing integrated machines in R&D and assessing repeatability, yields and design for manufacturability changes to improve first pass yield. They said it's very hardware-focused, reagents have been tracking to expectations, and they have enough Platinum Pro machines and consumables to work with customers in the interim. They haven't officially started early access and expect that early access timing will move out; they now expect to launch with either 19 or 20 amino acids and still expect to demonstrate all 20 this year, with any remaining amino acids added during 2027 if needed.
"With this shift in the timeline, we would expect that the early access will also move out." — Jeffrey Hawkins (CEO)
performance, manufacturing and costs
Q (Kyle Mikson · Canaccord Genuity): He asked how the extra cycle will affect performance and reproducibility, whether production time will be longer, and about exposure to chips. He also asked about non-human markets, AI interest, and timing of the $12 million OpEx savings.
A: Management said some internal instruments already perform above internal specifications while others are at or below, and the design cycle aims to make all instruments perform consistently at that higher level and simplify manufacturing. They said building machines took longer than expected but expect the next cycle and manufacturability changes to compress build time and increase yield; Proteus consumables are fused silica arrays (not CMOS chips), with only limited GPU exposure that can be buffered. They said Platinum gave them hands-on exposure to pathogen and agricultural markets, they are hearing AI-related interest and expect Proteus to help build training data, and the $12 million annualized savings will begin to show in the fourth quarter (second half of fourth quarter) as severance and transitions complete.
"We have some instruments that really reliably perform at a very high level, meaning above our internal specifications for the product." — Jeffrey Hawkins (CEO)
gating items and early access timing
Q (Charles Wallace · H.C. Wainwright): He asked what the specific gating items are before the second quarter of '27 and what is new. He also asked if the early access program is still planned and when it would start.
A: Management said the main gating item is the additional instrument design cycle: finalize the exact changes, roll them through manufacturing, build machines, and test them in-house through the remainder of this year. Assuming that goes well, they will integrate reagent and consumable work and aim for a launch in the second quarter. Early access has not started; they expect it after the design cycle, likely end of year or early 2027, and may allow customers to send samples for evaluation beforehand.
"So that cycle involves finalizing the exact changes we're going to make in that cycle, rolling that through manufacturing, building those machines and getting them in-house and tested." — Jeffrey Hawkins (CEO)
non-human market and amino acids impact
Q (Michael Okunewitch · Maxim Group): He asked whether the non-human proteomics market is mature enough for Proteus now or needs more academic work. He also asked how important moving from 17/18 amino acids to the full suite is for users.
A: Management said pathogen research and agricultural segments are already using Platinum devices and are ready today for Proteus, while other non-human areas (animal health, industrial, food, environmental) need more learning and are not central to near-term plans. On amino acids, they said moving from 18 to 19 and 20 mainly affects lower abundance amino acids and deep profiling use cases; for many applications the difference is small, but having all 20 simplifies sales conversations and removes a psychological barrier for customers.
"So we believe those markets are absolutely ready for the technology." — Jeffrey Hawkins (CEO)